Receipt of novel hormonal therapy for advanced prostate cancer varies with race


A study found that Medicare beneficiaries with advanced prostate cancer received different levels of novel hormonal therapy (NHT) depending on their race. The study, which included 3,748 men with advanced prostate cancer, found that 36 percent of the patients received NHT, with White patients having the highest utilization rates, followed by Hispanic patients, those with other race and ethnicity, and Black patients. Black patients were significantly less likely to receive NHT compared to White patients, which persisted at five years and beyond. The study suggests that future research is needed to address these disparities and provide more equitable care. Several authors involved in the study have financial ties to the pharmaceutical and medical device industries.

Source link

error: Content is protected !!